Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices
Helicobacter · 2024
DOI: 10.1111/hel.13152 ↗Kurz gefasst
Leitlinie in der Zeitschrift Helicobacter, 2024. Verfasst von Byung Wook Jung und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Republic of Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
Helicobacter pylori infects over 50% of the global population, prompting the issuance of guidelines for effective diagnosis and treatment. However, research on guideline dissemination and adherence is limited. Therefore, we assessed the nationwide status of H. pylori eradication therapies in Korea before and after guideline updates.
Methods
Using data from the Korean National Health Insurance Service, this retrospective cohort study analyzed changes in H. pylori eradication therapies across three periods: Phase I (2006–2007), Phase II (2014–2015), and Phase III (2021–2022). It examined therapy regimens, confirmation tests, and retreatment rates.
Results
Among 1,657,746 patients included, the number undergoing eradication therapy increased across the phases (Phase I: 234,365; Phase II: 493,889; Phase III: 929,492). The use of conventional triple therapy declined from 96.1% in Phase I to 88.3% in Phase III, while non‐bismuth and bismuth quadruple therapies increased to 6.8% and 3.3%, respectively, in Phase III. The proportion of patients following a 1‐week regimen of conventional triple therapy decreased from 90.3% in Phase I to 54.2% in Phase III, while a 2‐week regimen increased to 36.1% in Phase III. Confirmation testing within 1 year of therapy increased from 21.3% in Phase I to 43.0% in Phase III, whereas retreatment rates increased from 3.8% in Phase I to 8.8% in Phase III.
Conclusions
Guideline updates have influenced H. pylori eradication practices in Korea, leading to increased use of quadruple therapies with longer treatment durations. However, further improvements in confirmatory tests and retreatment following failed initial therapy are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Republic of Korea.
- Department of Medicine, Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Medicine, College of Medicine, Hanyang University, Seoul, Republic of Korea.
- Biostatistics Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Republic of Korea.
- Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, Namyangju, Republic of Korea.
ORCID-Profile: Byung Wook Jung, Chan Hyuk Park
Zitieren
APA
Jung, B. W., Kim, Y. J., & Park, C. H. (2024). Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices. Helicobacter. https://doi.org/10.1111/hel.13152
Vancouver
Jung BW, Kim YJ, Park CH. Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices. Helicobacter. 2024. doi:10.1111/hel.13152
BibTeX
@article{Jung2024,
author = {Jung, Byung Wook and Kim, Yun Jin and Park, Chan Hyuk},
title = {Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13152}
}
EUVIMED